Tags : Argenx

Argenx Signs a Worldwide License Agreement with Halozyme for its

Shots: Halozyme to receive $30M upfront, $160M milestones, $10M per future target nominations and royalties on sales of products. Argenx to get an exclusive license for Halozyme’s ENHANZE technology targeting ARGX-113 and additional two human neonatal Fc receptors (FcRn)   The focus of this ninth agreement b/w the companies, is to develop and commercialize neonatal […]Read More

Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for

Shots: The collaboration is focused on development of Larazotide for Alcoholic Liver Diseases (ALD), including severe alcoholic hepatitis Innovate will conduct an investor update on 17 Dec, 2018 for Larazotide, in celiac disease clinical program and NASH development strategy Larazotide (INN-202) is a synthetic eight amino acid peptide drug, completed P-II trial and expected to […]Read More

AbbVie Exercises Exclusive Option to License Argenx’s ARGX-115

Shots: AbbVie will obtain a worldwide, exclusive license to develop and commercialize ARGX-115-based products  Argenx to receive development, regulatory and commercial milestone payments of up to $625M, and has rights to co-promote ARGX-115 products in the EU and Swiss Economic Area Argenx and AbbVie previously entered into an option and license agreement for ARGX-115 in […]Read More